https://www.selleckchem.com/pr....oducts/ly2606368.htm
Clinical development of combination chemotherapies for tuberculosis (T is complicated by partial or restricted phase II dose-finding. Barriers include a propensity for drug resistance with monotherapy, practical limits on numbers of treatment arms for component dose combinations, and limited application of current dose selection methods to multidrug regimens. A multi-objective optimization approach to dose selection was developed as a conceptual and computational framework for currently evolving approaches to clinical testing of nov
Like
Comment
Share
